Ximelagatran was noninferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation: COMMENTARY

van Walraven, Carl
March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p39
Academic Journal
The article comments on the study conducted to examine the efficacy of ximelagatran over warfarin in patients with atrial fibrillation (AF) at moderate to high risk for thromboembolic outcomes. From a practical standpoint, ximelagatran is an easier drug to use than warfarin because it can be administered in a fixed-dose regimen, without the need for laboratory monitoring of its anticoagulant effect to make dose adjustments, and does not appear to have drug-and food-related interactions that occur with warfarin.


Related Articles

  • MANAGEMENT OF NONVALVULAR ATRIAL FIBRILLATION: A COMPREHENSIVE APPROACH. Iuliano, Luigi; Di Matteo, Antonio; Straface, Giuseppe // Indian Journal of Medical Sciences;Sep2009, Vol. 63 Issue 9, p419 

    Atrial fibrillation is the most common arrhythmia in clinical practice, may coexist with conditions common to both cardiovascular and noncardiovascular diseases and is associated with considerable morbidity and mortality. Atrial fibrillation is often asymptomatic and diagnosed only when it has...

  • Thrombophilia and Recurrent DVT. Artz, Andrew S. // Clinical Oncology Alert;Sep2009, Vol. 25 Issue 9, p68 

    WARFARIN IS AN EFFECTIVE AND INEXPENSIVE ORAL anticoagulation therapy used to prevent both venous and arterial thromboembolism. However, the narrow therapeutic window requires frequent monitoring, typically measured by the international normalized ratio (INR). Stable and long-term control of INR...

  • Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation. Yung Ly Kim; Boyoung Joung; Young Keun On; Chi Young Shim; Moon Hyoung Lee; Young-Hoon Kim; Hui-Nam Pak // Yonsei Medical Journal;1/1/2012, Vol. 53 Issue 1, p83 

    Purpose: Atrial fibrillation (AF) is one of the major risk factors for ischemic stroke, and 90% of thromboembolisms in these patients arise from the left atrial appendage (LAA). Recently, it has been documented that an LAA occlusion device (OD) is not inferior to warfarin therapy, and that it...

  • In AF requiring warfarin interruption, no anticoagulation bridging was noninferior to bridging for thromboembolism. Donato, Anthony // Annals of Internal Medicine;11/17/2015, Vol. 163 Issue 10, pJC5 

    The article presents questions and answers related to atrial fibrillation (AF) including no bridging noninferior to bridging with low-molecular-weight heparin (LMWH)for perioperative arterial thromboembolism (ATE) in patients with AF, and whether it reduces major bleeding.

  • Atrial Fibrillation and New Thromboembolic Stroke.  // American Family Physician;9/1/1996, Vol. 54 Issue 3, p1098 

    Presents an abstract of the study `Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients,' by W.S. Aronow et al, published in `Journal of American Geriatric Society.'

  • Risk Classification for Stroke, Death, and Atrial Fibrillation.  // American Family Physician;4/1/2004, Vol. 69 Issue 7, p1753 

    Presents a study on risk classification for stroke, death and atrial fibrillation (AF). Baseline risk factor data of the study; Number of participants who had stroke during a mean follow-up of 4.3 years; Number of participants who had stroke after excluding those who received warfarin;...

  • Left Atrial Appendage Occlusion � Closure or Just the Beginning? Maisel, William H. // New England Journal of Medicine;6/18/2009, Vol. 360 Issue 25, p2601 

    The author explores his views on left atrial appendage occlusion. He highlights the risk of stroke posed to three million Americans who have atrial fibrillation. He discusses the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) as the clinical trial for evaluating the...

  • Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation? Robertson, Sandy L.; Mayer, Jill Byerly // Journal of Family Practice;Jul2004, Vol. 53 Issue 7, p570 

    Adjusted-dose warfarin remains the most efficacious antithrombotic regimen for the primary and secondary prevention of cardioembolic stroke in high-risk patients with nonvalvular atrial fibrillation. Aspiring therapy at a dose of 75 to 325 milligrams reduces the risk of stroke to a lesser degree...

  • The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation. Davidson, Thomas; Husberg, Magnus; Janzon, Magnus; Levin, Lars-Åke // JAFIB: Journal of Atrial Fibrillation;Feb2011, Vol. 2 Issue 4, p870 

    Aim: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. People with AF have a significantly increased risk of thromboembolic events, including stroke, and the main treatment is therefore aimed at preventing thromboembolic events via anticoagulation with warfarin or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics